REGNHealthcare · Biotechnology

REGN Stock Forecast: Regeneron Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026

$803

−0.31% on the day

The 27 Wall Street analysts covering Regeneron Pharmaceuticals, Inc. hold a median 12-month price target of $809 — +0.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap

$82.7B

Ticker Nerd rank

92 / 100

Median analyst target

$809

Analysts covering

Total return, dividends reinvested

+2.4%

+22.5%

YTD

+4.4%

+42.7%

From 52W high

−0.8%

From 52W low

+45.2%

$553

$810

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

REGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Regeneron Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026

92 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value

Volatility

Revisions

Quality

Issuance

Momentum

Growth

Accruals

Size

Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (39): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (3): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

REGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on REGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says27 analysts

18 Buy9 Hold0 Sell

Low $641Median $809High $1,030

The green dot is the last close — the median target sits +0.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 5 moved it down.

Date	Firm	Action	Rating	Target
3 Aug 2026	Citigroup	Maintains	Neutral	$700 → $740
3 Aug 2026	Guggenheim	Maintains	Buy	$1,000 → $1,030
31 July 2026	Cantor Fitzgerald	Maintains	Overweight	$750 → $795
31 July 2026	Morgan Stanley	Maintains	Equal-Weight	$730 → $758
31 July 2026	RBC Capital	Maintains	Sector Perform	$696 → $737
31 July 2026	Truist Securities	Maintains	Buy	$769 → $772
31 July 2026	Wells Fargo	Maintains	Equal-Weight	$700 → $750
21 July 2026	Guggenheim	Maintains	Buy	$995 → $1,000
21 July 2026	Guggenheim	Maintains	Buy	—
9 July 2026	Piper Sandler	Maintains	Overweight	$855 → $854
9 July 2026	Piper Sandler	Maintains	Overweight	—
8 July 2026	Morgan Stanley	Maintains	Equal-Weight	$788 → $730
8 July 2026	Morgan Stanley	Maintains	Equal-Weight	—
7 July 2026	Benchmark	Upgrade	Buy	$185
7 July 2026	Benchmark	Upgrade	Buy	—
7 July 2026	RBC Capital	Maintains	Sector Perform	$707 → $696
7 July 2026	RBC Capital	Maintains	Sector Perform	—
7 July 2026	Truist Securities	Maintains	Buy	—
7 July 2026	Truist Securities	Maintains	Buy	$778 → $769
6 July 2026	Cantor Fitzgerald	Maintains	Overweight	$785 → $750

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. REGN appears on the weeks it earns a place.

Estimates

REGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

EPS revision, 90 days

+14.1%

Analysts raising

Analysts cutting

Fundamentals

Regeneron Pharmaceuticals, Inc. (REGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: 19.9×
Price / sales: 5.3×
Price / book: 2.5×
EV / EBITDA: 15.9×

Growth & margins

Revenue growth (YoY): 16.7%
Earnings growth (YoY): −6.8%
Gross margin: 86.6%
Operating margin: 33.1%
Net margin: 27.9%

Returns & dividend

Return on equity: 14.0%
Return on assets: 6.5%
Dividend yield: 0.5%

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

REGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
REGNRegeneron Pharmaceuticals, Inc.	$82.7B	92
VRTXVertex Pharmaceuticals, Inc.	$128.3B	67
RVMDRevolution Medicines, Inc.	$42.5B	35
RPRXRoyalty Pharma plc	$33.7B	86
ALNYAlnylam Pharmaceuticals, Inc.	$30.2B	54
INSMInsmed, Inc.	$27.0B	84
ROIVRoivant Sciences Ltd.	$25.9B	36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Regeneron Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest REGN news & analysis

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)

The Motley Fool · 14 Aug 2026positive

The article notes that GLP-1 demand is soaring and identifies two stocks that could benefit, excluding Eli Lilly and Novo Nordisk. It highlights that Regeneron has a pair of promising GLP-1 candidates in its pipeline.

Why it matters — REGN watchers would care because the article highlights Regeneron's GLP-1 pipeline candidates as potentially positioned to benefit from rising demand in the category.

FAQ

Frequently asked questions about REGN stock

What is the REGN stock price forecast for 2026-2027?

The 27 Wall Street analysts covering Regeneron Pharmaceuticals, Inc. have a median 12-month price target of $809, with estimates ranging from $641 to $1,030. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is REGN stock a buy right now?

Of the 27 analysts covering Regeneron Pharmaceuticals, Inc., 18 rate it a Buy, 9 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Regeneron Pharmaceuticals, Inc. 92 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank REGN?

As at 15 Aug 2026, Regeneron Pharmaceuticals, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).

Will REGN stock go up?

No one can know that. What the data says: the median 12-month target from 27 analysts implies +0.6% from the last close, and Ticker Nerd's factor model ranks Regeneron Pharmaceuticals, Inc. 92 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the REGN stock forecast for 2030?

No analyst covering Regeneron Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for REGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $641 to $1,030 over the next 12 months.

How has REGN stock performed over the past year?

Regeneron Pharmaceuticals, Inc. returned +42.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Regeneron Pharmaceuticals, Inc. do?

What is the latest news on REGN?

The most recent item we track (The Motley Fool, 14 Aug 2026): "GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)". The article notes that GLP-1 demand is soaring and identifies two stocks that could benefit, excluding Eli Lilly and Novo Nordisk. It highlights that Regeneron has a pair of promising GLP-1 candidates in its pipeline.

Company

About Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases across eye care, immunology, oncology, cardiovascular health, and inflammation. Its current portfolio includes treatments such as Eylea and Eylea HD for retinal and eye disorders, Dupixent for inflammatory and allergic conditions, Praluent for cholesterol management, Libtayo in oncology, and Kevzara for rheumatoid arthritis. Regeneron also works on antibody-based medicines and collaborates with partners on advanced research programs, supporting a broad pipeline of therapies. The company serves patients, healthcare providers, and medical systems through prescription medicines used in specialist and hospital care settings. Headquartered in Tarrytown, New York, Regeneron plays a significant role in the biotechnology market by combining drug development, manufacturing, and commercialization across multiple therapeutic areas.

CEO Dr. Leonard S. Schleifer M.D., Ph.D. · 15,410 employees · United States · https://www.regeneron.com